We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Silence Therapeutics Plc | LSE:SLN | London | Ordinary Share | GB00B9GTXM62 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 535.00 | 521.00 | 524.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
28/3/2019 16:09 | My employer's SIPP contribution comes through then | volsung | |
27/3/2019 17:00 | I will be averaging down on or around 8th April | volsung | |
26/3/2019 18:25 | Anyone brave enough to average down? | djnzloop | |
22/3/2019 12:58 | Fine,could you comment on the huge difference between share prices over the last year,whilst they are both in the same fundamental business.What is Arrowhead doing that Silence is not.Maybe they could replicate. | tshirley12 | |
22/3/2019 11:58 | "What other assets does Silence have other than their.I.P. Is there a danger of Silence running out of funding,and when." Cash of £26.5m as at 31/12/18 and enough to take them into 2nd half 2020. "What happened to ATUO27". - discontinued. "What other assets does Silence have other than their.I.P." Cash of £26,5m plus milestone and licensing agreements for 2 Quark products "As anybody got any idea how much they received from their Alnylam agreement" Between 0.33% and 1% of Patisiran sales in Europe up till 2023. Actual amount depends on level of Patisiran sales. "As there's no sign of a takeover,are there any possibilities of a merger with anybody" - who knows! | callumross | |
22/3/2019 10:32 | A few questions,would appreciate any comments.Firstly over the last year the share price has fallen from a peak of 250p to less than 50p.today.Whilst Arrowheads share price as more or less quadrupled,what is Silence doing that is fundamentally different to justify the crash. What other assets does Silence have other than their.I.P. Is there a danger of Silence running out of funding,and when. As anybody got any idea how much they received from their Alnylam agreement. What happened to ATUO27. As there's no sign of a takeover,are there any possibilities of a merger with anybody. Now waiting on the results from Quark,if this doesn't go as well as hoped, where does that leave us. As I said I would appreciate any comments as I am looking at all avenues before I decide to bail out. | tshirley12 | |
15/3/2019 19:11 | I was wondering if we had been played with that Ali move. Just as all the C level quits he flies the flag big time .... | djnzloop | |
15/3/2019 17:08 | Yes, it's not encouraging is it, especially on the patent climbdown? I cling to the hope that Ali knew what he was doing when he increased his holding materially last year (5th October rns). A good announcement from Quark around their interpretive results would help to restore my faith that there is at least some basis to the science at this point. | 1gw | |
12/3/2019 19:04 | Arrowhead now at around $20 & current management folding before the finish line after £4 mil legal fee spend. This lot look destined to waste what's left of the pot & then hope the spend will enable inroads to new jobs. I reckon the 2.30 at Chepstow would be a fairer bet | djnzloop | |
11/3/2019 10:02 | Quark completed dosing of 594 patients in a Phase III study for delayed graft function (DGF) following kidney transplantation in January 2018, with first interpretative results anticipated imminently | callumross | |
11/3/2019 07:20 | 'We remain focussed and determined to be responsive to shareholder value and also chart the right course for our business to see appropriate growth, and development. To this end we continue to assess a number of options in addition to our organic plan which we believe would be additive to the Company's future growth prospects and shareholder value' ..........zzzzzzzzzz | soundbuy | |
08/3/2019 07:41 | Note that Quark have moved into a full phase 3 in kidney function. Did SLN get any milestone? | waterloo01 | |
07/3/2019 12:17 | Any ideas about results monday ? | tarlok | |
07/3/2019 08:26 | Silent as the grave | volsung | |
14/2/2019 12:31 | www.optcongress.com/ SLN and Quark presenting here | rnainvestor | |
14/2/2019 12:23 | www.optcongress.com | rnainvestor | |
14/2/2019 12:22 | www.optcongress.com/ | rnainvestor | |
05/2/2019 15:18 | Dear SLN Could you do a VAL soon? Kind regards volsung | volsung | |
31/1/2019 15:41 | Think they've shut up shop | djnzloop | |
31/1/2019 14:43 | Isn't it about time we heard something about Quark's trial? | 1gw | |
24/1/2019 15:27 | Av now 112p | volsung | |
24/1/2019 15:27 | Bought some more at 48.72p Looks like I'm going down with the ship! | volsung | |
24/1/2019 15:13 | With all this selling still no holding rns? | djnzloop |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions